Ongoing Research to Watch at ASH 2025 and Beyond

Jonathan Webster, MD, and Nikesh Shah, MD, highlight key ALL data anticipated at the 2025 ASH Annual Meeting, including updates from pivotal immunotherapy studies and trials exploring targeted agents. They discuss how these findings may refine treatment selection, deepen understanding of MRD-guided care, and influence long-term management strategies. They also identify emerging areas of scientific interest that may define the next wave of innovation in ALL research.